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Abstract
Background: To determine morphological and functional cardiovascular magnetic resonance (CMR) patterns in
histopathologically confirmed myocardial involvement in patients with systemic sclerosis (SSc).
Methods: Twenty patients (6 females; mean age 41 ± 11 years) with histopathologically proven cardiac involvement in
SSc in the years 2008–2016 were retrospectively evaluated. Morphological, functional and late gadolinium enhancement
(LGE) images were acquired in standard angulations at 1.5 T CMR. Pathologies were categorized: 1) Pericardial effusion; 2)
pathologic left (LV) or right ventricular (RV) contractility (hypokinesia, dyssynchrony, and diastolic restriction); 3) reduced
left (LV-EF) and right ventricular ejection fraction (RV-EF); 4) fibrosis and/or inflammation (positive LGE); 5) RV dilatation.
95 % confidence intervals (CI) were calculated for appearance of pathologic EF and RV dilatation.
Results: Seven patients (35 %) had positive CMR findings in three categories, 9 patients (45 %) in four categories and 4
patients (20 %) in five categories. The distribution of pathologic findings was: minimal pericardial effusion in 7 patients
(35 %), moderate pericardial effusion >5 mm in nine patients (45 %); abnormal LV or RV contractility in 19 patients (95 %),
reduced LV or RV function in 14 patients (70 %; 95 % CI: 51–88 %), pathologic LGE in all patients, RV dilatation in 6
patients (30 %; 95 % CI: 15–54 %).
Conclusions: CMR diagnosis of myocardial involvement in SSc requires increased attention to subtle findings. Pathologic
findings in at least three of five categories indicate myocardial involvement in SSc.
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Background
Systemic sclerosis (SSc) is a rare chronic systemic auto-
immune disease associated with different autoantibodies,
the most common are anti-topoisomerase I (Anti-Scl-70)
and anti-centromere antibodies (ACA). SSc is associated
with high morbidity and mortality [1]. The pathogenesis of
SSc is not entirely understood but microvascular changes
are suspected to be the main cause of connective tissue
infiltration and fibrosis [2]. Besides cutaneous manifesta-
tions, visceral involvement especially of bowel, lung, heart
and kidney is more common and occurs earlier in patients
with diffuse cutaneous subset of SSc (dcSSc) than in
patients with limited cutaneous SSc (lcSSc) [3, 4]. In
general, the prognosis in patients with myocardial involve-
ment is poor [2].
In these patients with cardiac involvement, non-
segmental perfusion defects can be observed in myocardial
stress perfusion cardiovascular magnetic resonance (CMR),
suggesting resemblances in the pathogenesis of SSc associ-
ated Raynaud’s phenomenon and transient myocardial
ischemia [5]. Cardiac Raynaud’s phenomenon may be one
reason for subsequent myocardial fibrosis, in addition to
non-specific hypertrophy.
Several CMR studies have pointed out characteristic
findings in patients with SSc. These are: Pericardial
effusion [6], left ventricular (LV) and right ventricular
(RV) diastolic and systolic dysfunction, LV hypertrophy,
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perfusion defects and myocardial late gadolinium
enhancement (LGE) [5, 7–10].
Standard treatment of SSc includes cyclophosphamide,
which can be cardiotoxic [11]. In our patient group with
severe scleroderma, CMR was part of a routine diagnos-
tic work up in the course of preparation and risk stratifi-
cation for autologous stem cell transplantation and
escalation of potentially cardiotoxic therapy. Myocardial
histopathological fibrosis and inflammation in SSc is by
trend associated with cardiac events [12].
Aim of this study was to systematically determine
morphological and functional CMR imaging patterns in
systemic sclerosis in patients with histopathologically
confirmed myocardial involvement in SSc.
Methods
Study population
Twenty patients (6 female, 14 male; mean age 40.7 ±
10.8 years; range [19; 56] years) with a history of SSc for
3.0 years (±2.9 years; range [0.5; 10] years) were retro-
spectively included. One patient had lcSSc, 19 had
dcSSc. The mean modified Rodnan skin score was 26
(±11; range [4; 45]). Troponin I was elevated in 13
patients (65 %), brain natriuretic peptide in 6 patients
(30 %). Anti-Scl-70 antibodies were positive in 15
patients (75 %), additionally anti-centromere antibodies
were positive in two patients (10 %). Three patients
(15 %) had pulmonary arterial hypertension, seven
patients (35 %) had pathologic Holter ECG.
This study retrospectively evaluated a subpopulation of
patients with cardiac involvement in SSc as proven by
endomyocardial biopsy (EMB) previously undergoing CMR
in the years 2008–2016. Clinical findings in a part of the
study group (16 patients) were published by Mueller et al.
[12]. All patients were clinically diagnosed by an experi-
enced rheumatologist according to the 2013 criteria of the
American College of Rheumatology [13]. None of the
patients presented with symptoms of cardiac failure. For
clinical and laboratory suspicion of myocardial involve-
ment, patients underwent EMB including histopathologic,
immunohistologic and molecular pathological evaluation at
median 14 days after CMR.
Endomyocardial biopsy and analysis
EMB was sampled from the right ventricular septum.
Histopathological and immunohistological analyses were
performed by experienced cardiopathologists as
described by Mueller et. al. [12]: The degree of fibrosis
was rated in percent of the biopsy area. Inflammation
was graded 0–4: grade 0 = no inflammation; 1 = single
inflammatory cells; 2 = few foci of inflammation; grade 3
= several foci of inflammation; grade 4 = pronounced
inflammation. Molecular detection of viral genomes was
performed.
CMR acquisition
CMR was performed on a 1.5 T scanner (Magnetom
Avanto, Siemens Healthcare, Erlangen, Germany) equipped
with a gradient system with a maximum strength of 45
mT/m and a maximum slew rate of 200 T/m/s. A six
channel body array coil and six coils of the spine coil were
used for reception of MR-signals. All images were acquired
in breath hold technique with ECG triggering.
For functional imaging, Steady State Free Precession
(SSFP) cine loops (repetition time (TR) 3 ms; echo time
(TE) 1.5 ms; flip angle 60°, slice thickness 5 mm; matrix
256x192; 25 frames per cardiac cycle) were acquired in
standard angulations: four-chamber view (4CV), two-
chamber view (2CV) and a stack of short-axis slices (gap
5 mm) covering both entire ventricles from base to apex.
For anatomical overview, a T2w Half-fourier Acquisition
Single-shot Turbo Spin-Echo (HASTE) in 5 mm gapless
axial slices covering the thorax was performed. Optimal
inversion time (TI) was determined with an inversion
time localizer (TI Scout) SSFP, magnetization prepar-
ation: slice selective inversion pulse, 20 ms increment
for inversion recovery measurement, (TR 24 ms, TE
1.12 ms, flip angle 60°, slice thickness 8 mm). The inver-
sion time localizer was acquired 9 min after administra-
tion of 0.15 mmol Gadobutrol per kg body weight
(Gadovist, Bayer Healthcare, Leverkusen, Germany) in a
mid-cavity short-axis slice. LGE imaging was performed
10–15 min after contrast agent application with a 2D
T1-weighted inversion recovery spoiled gradient echo
sequence (segmented k-space readout, TR 8.0 ms, TE
4.9, TI as predetermined and incrementally adapted, flip
angle 30°, slice thickness 8 mm) in standard angulations
with corresponding slice positions to the functional
imaging sequences. For all sequences, the field of view
was 280–340 mm adapted to patient’s size, kept to a
minimum, respectively.
Image analysis
Image analysis for the retrospective study analysis was
performed by two independent readers (eleven and five
years of experience in cardiac imaging), aware of the
histopathologic biopsy result, using an offline worksta-
tion CVI42 (Circle Cardiovascular Imaging, Calgary AB,
Canada). Initial reading of the images in clinical routine
had been performed by different readers, blinded to the
result of the subsequent biopsy. The results of the initial
reports were evaluated categorically in ‘cardiac SSc
involvement’ and ‘no cardiac SSc involvement’.
Morphology and function
Contractility was evaluated according to the following
criteria: Presence of hypokinesia, dyskinesia, intraventricu-
lar synchrony, and diastolic function for both ventricles
respectively, in a visual qualitative analysis.
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Functional parameters were determined by volumetry
of the left and right ventricle in a stack of short-axis
slices according to the modified Simpson rule [14]. End-
diastole and end-systole were determined manually.
Endocardial contours were drawn with help of a semi-
automated region growing algorithm in both ventricles.
Epicardial contours of the left ventricle were drawn
manually. Left ventricular end-diastolic volume (LV-
EDV) with the corresponding left ventricular end-
diastolic volume index (LV-EDVI) normalized to body
surface area (BSA), left ventricular ejection fraction (LV-
EF) as well as left ventricular myocardial mass (LV-MM)
and the respective index (LV-MMI) were calculated.
Accordingly, right ventricular end-diastolic volume (RV-
EDV), right ventricular end-diastolic volume index (RV-
EDVI) and right ventricular ejection fraction (RV-EF)
were assessed. Ventricular dilatation was determined
according to the recently published criteria by Kawel-
Boehm et al. 2015 [15]. Ventricles were classified as
dilated if the ventricular end-diastolic volume index was
above the upper limit calculated as mean +2 standard
deviations (SD) of the normal collective regarding gen-
der and age <60 years: LV-EDVI >95 ml/m2 for females,
>100 ml/m2 for males; RV-EDVI >96 ml/m2 for females,
>111 ml/m2 for males. The ventricular function was
classified as reduced, if the ejection fraction was below
the lower limit calculated as mean -2SD of the normal
collective considering gender and age <60 years: LV-EF
<58 % for females, <57 % for males; RV-EF <52 % for
females, <50 % for males. LV-MM was classified as
increased, if LV-MMI was above the upper limit deter-
mined as mean +2SD of the normal collective consider-
ing gender and age <60 years: LV-MMI >77 g/m2 for
females, >91 g/m2 for males.
Additionally, the right ventricular diameter was mea-
sured in four-chamber view 4CV. RV dilatation was
assumed if cross-section dimension in 4CV and basal
short-axis was above two standard deviations of the nor-
mal value according to Hergan et al. [16].
LV myocardial thickness was evaluated in a mid-
ventricular short-axis slice in segment 9 (inferoseptal)
and 11 (inferolateral) and rated according to Kawel et al.
[17]: LV myocardium was considered hypertrophic in
segment 9 exceeding 9.3 mm (women) and 11.4 mm
(men), respectively; in segment 11 exceeding 7.5 mm
(women) and 9.1 mm (men).
RV myocardial thickness was measured in the
posterior wall in a mid-ventricular short-axis slice. RV
hypertrophy was assumed if RV wall thickness was
5 mm or higher [18, 19]. Maximum thickness of
pericardial effusion was measured in end-diastole in
Steady State Free Precession (SSFP) cine loops.
Pericardial effusion was classified minimal ≤5 mm
pericardial space, and moderate >5 mm [20].
Late Gadolinium enhancement and inversion time localizer
Inversion time localizer nulling patterns of the myocar-
dium and blood pool were categorized by the nulling
type patterns 1 (normal) and the abnormal patterns 2–4
as imposed by Pandey et al. [21]: Physiologic type 1
nulling pattern: blood pool nulls first, followed by
myocardium and spleen at the same time. Pathologic
type 2 nulling pattern: myocardium nulls first, followed
by blood pool and spleen at the same time. Pathologic
type 3 nulling pattern: myocardium and blood pool null
simultaneously, followed by the spleen. Pathologic Type
4 nulling pattern: myocardium, blood pool and spleen all
null at different times.
LGE was evaluated qualitatively and semi-quantitatively.
Datasets in which the Inversion Time (TI) Scout indicated
an insufficient nulling of the myocardium in contrast to
the blood pool were excluded from LGE quantification.
For quantification of LGE contours in all short axis slices
were drawn manually with care to exclude pericardial fat
and blood pool at the myocardial borders. For visual
reading and semi-automated thresholding, the recommen-
dations of the Society for Cardiovascular Magnetic Reson-
ance Task Force were adopted [22]: signal intensity >5
standard deviations of the normal myocardium was con-
sidered as full intensity LGE. In addition, a grayscale ana-
lysis of intermediate-signal intensity LGE was performed
(≥2SD but <5SD of the normal myocardium). Full inten-
sity and intermediate intensity LGE were recorded in % of
the myocardial mass. Inversion time for the first and last
LGE image was recorded.
Statistical analysis
Statistical analysis was performed using JMP (Version
12.2, SAS Institute Inc., Cary NC, USA). All continuous
variables are expressed as mean value ± standard deviation
and range in square brackets. Interobserver-variability for
continuous variables was evaluated with Bland-Altman
difference plots. Mean difference and the limits of agree-
ment defined as ±1.96 SD were calculated for LV-EDV,
LV-EF, RV-EDV and RV-EF. Over all categorical variables
in visual analysis interobserver-agreement was measured
with Cohen’s Kappa. Paired two-sided t-test was applied
for null hypothesis if Kappa equals zero. Agreement in
Kappa statistic was rated according to Landis and Koch
[23]: ‘moderate’ (0.41–0.6), ‘substantial’ (0.61–0.8), and
‘almost perfect’ (0.81–1).
To test if among the study cohort more than the 2.5 %
of the normal collective had pathologic values, 95 %
confidence interval (CI) was calculated for the quotient
pathologic sample/total sample for LV-EF, RV-EF, LV-
EDVI, and RV-EDVI. Higher occurrence of pathologic
values in the study cohort was assumed if lower 95 % CI
was above 2.5 %. Normal distribution for each value was
assessed visually in curves.
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To determine how many pathologic findings occurred in
one patient, CMR findings were categorized: 1) moderate
pericardial effusion; 2) ventricular kinesic pattern (LV and
RV hypokinesia, dyskinesia, dyssynchrony, and diastolic
restriction); 3) reduced ventricular function (reduced LV-EF
or LV-EF); 4) suspect for fibrosis and inflammation (positive
LGE); 5) right ventricular dilatation.
Results
Endomyocardial biopsy results
Myocardial fibrosis was found in all patients. The mean
degree of myocardial fibrosis over all patients was 12.3 %
(±6.3 %; [4 %; 32 %]). Five patients (25 %) had an inflam-
mation grade 1; ten patients (50 %) grade 2; five patients
(25 %) grade 3. One patient had 300 copies/μg myocar-
dial DNA of parvovirus B19 genotype 1, indicating virus
persistence.
Morphology and function
In visual motion analysis, septal regional LV hypokinesia
was found in 15 patients (75 %); LV intraventricular
dyssynchrony in 13 patients (65 %); and LV diastolic
dysfunction of a restrictive pattern with passive filling in
17 patients (85 %). Regional or global RV hypokinesia
was found in 14 patients (70 %); RV dyskinesia in 2
patients (10 %); RV intraventricular dyssynchrony in 12
patients (60 %); and restrictive RV diastolic dysfunction
in 13 patients (65 %). 19 patients (95 %) had pathologic
LV and or RV ventricular kinesia pattern (CMR cine
loops see Additional file 1 and Additional file 2).
The volumetric analysis indicated left ventricular dila-
tation in 4 patients (20 %; 95%CI: 8–41 %) and right
ventricular dilatation in 6 patients (30 %; 95%CI: 15–
54 %). Ventricular function was reduced in 14 patients:
14 patients (70 %; 95%CI: 51–88 %) had reduced RV-EF;
10 of which (50 %; 95%CI: 30–70 %) had both reduced
LV-EF and RV-EF. Increased LV-MMI was found in two
patients (10 %) by left ventricular myocardial mass volu-
metry (Table 1). The mean right ventricular diameter
was 48.7 mm (±7 mm; [35 mm; 59 mm]). 16 patients
(80 %) had RV diameters exceeding the upper limit for
normal RV diameter (Fig. 1).
End-diastolic myocardial thickness of the LV in the
mid-ventricular septum (segment 9) was 10.4 mm
(±1.8 mm; [8 mm; 14 mm]), in the inferolateral wall (seg-
ment 11) 8.1 mm (±1.8 mm; [5 mm; 11 mm]). 7 patients
(35 %) had septal myocardial hypertrophy (segment 9), 7
patients (35 %) had inferolateral myocardial hypertrophy
(segment 11). Five of these patients had septal and infero-
lateral myocardial hypertrophy, 2 patients had asymmetric
septal hypertrophy.
RV Myocardial thickness was 3.3 mm (±1.2 mm;
[1 mm; 5 mm]), normal 1–4 mm in 18 patients (90 %),
and pathologic 5 mm in two patients (10 %).
Seven patients (35 %) had minimal pericardial
effusion, nine patients (45 %) had moderate pericardial
effusion >5 mm (Fig. 2 and Additional file 1 and
Additional file 2).
Inversion time localizer
Inversion time localizer was not evaluable in three
patients. Physiologic type 1 nulling pattern was found in
eight of the evaluable 17 patients (47 %). Pathologic
nulling patterns were found in nine patients (53 %):
Type 2 in two patients (12 %); type 3 in five patients
(29 %, Fig. 3), type 4 in two patients (12 %).
Late Gadolinium Enhancement
LGE imaging was not evaluable in one patient due to
breathing artifacts. In the visual analysis, three of 19 pa-
tients (16 %) had intermediate signal-intensity LGE in
linear and patchy pattern (Fig. 1). Ten patients (53 %)
had diffuse LGE. Two of these patients had generalized
LGE with no reasonable nulling of the myocardium
(Figs. 2 and 3), they were excluded from semi-
quantitative analysis.
In the semi-quantitative analysis, pathologic LGE was
found in all patients: full intensity LGE was found in
5.1 % (±3.4 %; [0 %; 11 %]) of the LV myocardial mass in
patchy and linear patterns. Intermediate-signal intensity
LGE was found in 25.9 % (±5.7 %; [17 %; 37 %]) of the
LV myocardial mass.
Inversion time for LGE imaging has been set to
283 ms (±25 ms; [230 ms; 320 ms]) for the first image,
for the last image to 312 ms (±34 ms; [260 ms; 380 ms]).
TI was elevated from first to last LGE image for 28 ms
(±23 ms; [0 ms; 80 ms]).
All results are summarized by frequency in Table 2.
In evaluation of the initial clinical CMR reports
blinded to subsequent EMB, the report was diagnosing
‘cardiac SSc involvement’ in 6 patients (30 %).




LV-EF 57 % (±7 %;
[39 %; 70 %])
LV-EDV 137 ml (±43 ml;
[80 ml; 210 ml])
73 ml/m2 (±21 ml/m2;
[38 ml/m2; 105 ml/m2])
LV-MM 124 g (±31 g;
[79 g; 205 g])
65 g/m2 (±17 g/m2;
[26 g/m2; 111 g/m2])
RV-EF 45 % (±7 %;
[28 %; 57 %])
RV-EDV 167 ml (±43 ml;
[105 ml; 242 ml])
89 ml/m2 (±20 ml/m2;
[50 ml/m2; 117 ml/m2])
BSA Body Surface area inm2, LV-EF Left ventricular ejection fraction, LV-EDV Left
ventricular end-diastolic volume, LV-MM Left ventricular myocardial mass, RV-EDV
Right ventricular end-diastolic volume, RV-EF Right ventricular ejection fraction
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Statistical analysis
The interobserver variability analysis indicated a mean
difference for LV-EDV of -1.8 ml with limits of agree-
ment -11.4 ml; 7.9 ml. The mean difference for LV-EF
was 0.7 %, limits of agreement were -5.5 %; 7 %. The
mean difference for RV-EDV was 1.7 ml, limits of agree-
ment were -7.9 ml; 11.4 ml. The mean difference for
RV-EF was 0.2 %, limits of agreement were -5.7 %; 6.1 %.
Kappa statistic for interobserver-agreement in categor-
ical variables was ‘almost perfect’ 0.913, p < 0.0001. LV-
EF, RV-EF, LV-EDVI, and RV-EDVI were normally
distributed.
In categorical analysis of pathologic CMR findings,
seven patients (35 %) had positive findings in three
categories, nine patients (45 %) in four categories, and
four patients (20 %) in five categories.
Discussion
In the present study we systematically evaluated CMR
findings in a rare subgroup of SSc patients with histo-
pathologically confirmed myocardial involvement.
In CMR, pathologic findings were documented in all
SSc patients, confirming a high occurrence of abnormal
volumetric data as compared to normal healthy collec-
tives (95%CI). Diastolic dysfunction is known to develop
early in the course of myocardial involvement in SSc
even before the appearance of clinical symptoms [24].
The pericardial effusion found in the majority of our
patients is known to be common in SSc [25], and might
contribute to the development of diastolic dysfunction
[26]. Pericardial effusion is also common in pulmonary
arterial hypertension [25], reflecting the complexity of
cardiopulmonary involvement in SSc. Notably, a number
of patients only had a slight or minimal pericardial
effusion, that will commonly be classified as unspecific.
Regional or global enhancement by LGE imaging
indicating myocardial fibrosis can be regarded as
morphologic correlate for restricted diastolic and systolic
function as well as for myocardial electrical conduction
disorders, potentially resulting in ventricular dyssyn-
chrony. RV dilatation occurred independently from
pulmonary hypertension in a relevant number of
patients, a phenomenon that has already been described
previously [9]. In this context, RV dilatation may indi-
cate RV involvement as a primary symptom in contrast
to secondary dilatation.
In visual reading and semi-quantitative evaluation, we
found typical non-coronary distribution of full intensity
LGE as described before: a linear enhancement [7]; as
well as patchy pattern at the insertion points of the right
ventricle—which is also typically found in hypertrophy
and pulmonary artery hypertension, the latter being
frequently co-existent due to severe lung involvement in
SSc patients [27]. In the semi-quantitative evaluation,
grayscale intermediate intensity LGE was most frequent.
We performed semi-quantitative T1 evaluation with an
ordinal scale by means of the inversion time localizer.
Pathologic nulling patterns of inversion time localizer
were common in our patient group, indicating severe
diffuse myocardial fibrosis. Diffuse myocardial fibrosis
frequently evades visual detection and is significantly
underestimated in LGE quantification, for nulling of the
myocardium suppresses general enhancement by shifting
the threshold [28]. As a result, diffusely involved myo-
cardium may appear normal. In semi-quantitative LGE
evaluation, the region of interest for remote myocardium
may be placed in regions with less but still pathologic
contrast enhancement, visually not identified as such.
Although diffuse general fibrosis can be detected and
quantified using T1-mapping, the values remain unspe-
cific for diffuse fibrosis [29]. We did not find a ‘runaway’
TI with initially short TI and large incremental steps
during image acquisition, which is known to be typical
for amyloidosis [30]. In consequence, non-invasive
assessment of the extent of myocardial fibrosis in SSc
remains challenging and the implication of imaging
findings for prognosis and further treatment remains
uncertain. Fibrosis in biopsy may only correlate with T1-
Fig. 1 Depicts typical, subtle findings in myocardial involvement in SSc in a female patient: a Right ventricular dilatation in SSFP 4CV (star). Cine
loop is available in Additional file 1 to depict characteristically left ventricular and right ventricular restrictive filling pattern. LGE images in 4CV (b),
and mid-ventricular SA (c) depict mid-myocyardial intermediate-signal intensity linear (arrow) and patchy (arrowhead) LGE. 4CV: Four-chamber
view; LGE: Late Gadolinium Enhancement; SA: Short-axis; SSFP: Steady State Free Precession
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mapping for absolute quantification of fibrosis. None of
our parameters is likely to correlate with fibrosis in
biopsy: LGE does shift threshold of healthy towards
pathologic when nulling myocardium, and functional
parameters are subject to situational adaption. Extent of
cardiac involvement in SSc is not necessarily dependent
on other objectively verifiable parameters and subject to
subclinical periods, primary or secondary involvement
and influenced by cardiotoxic therapy [2, 12].
CMR is accepted as one of the non-invasive modalities
to investigate SSc involvement of the heart [31]. Yet, to
determine the degree of cardiac involvement seems to be
difficult even for experienced readers. To date, criteria for
the CMR diagnosis of myocardial involvement in SSc are
not defined. CMR was performed and evaluated before
EMB in all patients, so that no influence on imaging and
initial blinded reading can be stated.
As systolic dysfunction is a rare finding in SSc, the
severity of the involvement tends to be underestimated
[32]. Based on the inversion time localizer principle, T1-
mapping should be a promising method to further inves-
tigate diffuse myocardial fibrosis in SSc involvement
[29]. T1-mapping does not require healthy remote myo-
cardium to detect diffuse fibrosis. Extracellular volume
determination in T1-mapping has recently shown the
potential to correlate with myocardial fibrosis [33].
Our results might contribute to improve the non-
invasive diagnosis of cardiac involvement in SSc, using
CMR to identify and estimate cardiac involvement.
Discrete CMR imaging patterns could be found concur-
rently, also in severe SSc myocardial involvement. In our
retrospective evaluation, myocardial involvement in SSc
was systematically underdiagnosed in the initial clinical
report blinded to the subsequent histopathologic work-
up with true positive diagnoses in only 30 % of our SSc
cohort. The main reason may be underestimation of
subtle morphologic and functional findings in SSc
involvement, as this is a rare cardiac diagnosis. To date,
mainly CMR findings in the maximum degree of occur-
rence have been published, potentially leading to a trend
to underestimate subtle, yet SSc-typical, findings. Most
CMR findings appear to be unspecific and can be found
in a variety of diseases. However, the combination of
certain findings as described in our work seems to be
characteristic for cardiac SSc involvement. For the lack
of correlation, CMR cannot replace EMB. EMB itself is
rarely performed in a clinical setting. Application of the
proposed criteria may improve assessment of clinically
relevant SSc involvement. Although CMR findings in pa-
tients with cardiac involvement in SSc can easily go
underdiagnosed and classified as unspecific, the combin-
ation of several CMR findings is frequent and therefore
allows the diagnosis of cardiac involvement in patients
with SSc by CMR: Besides distinct LGE patterns, most
important findings are involvement of both ventricles,
pathologic LV/RV contractility, dyssynchrony or restric-
tion. Reading of inversion time localizer for diffuse LGE
and can be easily implemented without additional
technical requirements.
This approach might be useful for risk stratification
when considering therapeutic options, and may eventually
Fig. 2 Depicts septal hypertrophy (arrow) and moderate pericardial
effusion (arrowhead) in a female patient in mid-ventricular short-axis
SSFP imaging (a). In LGE imaging (b) of the same slice no sufficient
nulling of the myocardium (arrow) in contrast to the blood pool
(star) was possible due to diffuse LGE in diffuse fibrosis without
remote and healthy myocardium. The finding may be misinterpreted
as technical failure. LGE: Late Gadolinium Enhancement; SSFP: Steady
State Free Precession
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Table 2 Frequency of abnormal CMR findings
Pathology Frequency Appearance Normal value
pathologic LV and or RV ventricular
kinesic pattern
95 % -
LV diastolic dysfunction 85 % -
LV hypokinesia 75 % -
RV hypokinesia 70 % -
RV diastolic dysfunction 65 % -
LV intraventricular dyssynchrony 65 % -
RV intraventricular dyssynchrony 60 % -
RV dyskinesia 10 % -
Pericardial Effusion 80 %
Minimal Effusion 35 % ≤5 mm
Moderate Effusion 45 % >5 mm ≤5 mm [20]
RV-EF 74 % below -2SD of normal ≥52 % (f); ≥50 % (m) ; <60 years [15]
LV-EF 50 % below -2SD of normal ≥58 % (f); ≥57 % (m) ; <60 years [15]
RV-EDVI 32 % above +2SD of normal ≤96 ml/m2 (f); ≤111 ml/m2 (m) ; <60 years [15]
LV-EDVI 20 % above +2SD of normal ≤95 ml/m2 (f); ≤100 ml/m2 (m) ; <60 years [15]
LV-MMI 10 % above +2SD of normal ≤77 g/m2 (f); ≤91 g/m2 (m); <60 years [15]
RV EDD in 4CV 80 % above +2SD of normal <39 mm (f); <49 mm (m) [16]
LV myocardial thickness 35 % above +2SD of normal Segment 9: ≤9.3 mm (f); ≤11.4 mm (m) Segment 11: ≤7.5 mm (f); ≤9.1
mm (m) [17]
RV myocardial thickness 10 % ≥5 mm <5 mm [18, 19]
Inversion time localizer 50 % Pathologic nulling pattern Blood nulls first, myocardium and spleen second [21]
LGE visual analysis 69 % -
Visual diffuse 53 % diffuse, or no reasonable
nulling
-
intermediate-signal intensity 16 % linear and patchy -
LGE semi-quantitative analysis 100 %
intermediate-signal intensity 100 % 17–37 % of LV mass -
full intensity 94 % 0–11 % of LV mass -
4CV Four-chamber view, EDD End-diastolic diameter, LGE Late Gadolinium enhancement, LV left ventricle, LV-EDVI Left ventricular end-diastolic volume index, LV-EF
Left ventricular ejection fraction, LV-MMI Left ventricular myocardial mass index, RV right ventricle, RV-EDVI Right ventricular end-diastolic volume index, RV-EF Right
ventricular ejection fraction, SD Standard deviation
Fig. 3 Depicts pathologic type 3 nulling pattern of myocardium in inversion time localizer in a male patient according to Pandey et. al. [21].
Images depict a basal short-axis slice with different inversion times (TI): a TI 80 ms; b TI 160 ms; c TI 240 ms; d TI 320 ms. Myocardium (arrow)
and blood pool (star) null simultaneously, followed by the spleen (arrowhead). This phenomenon indicates diffuse gadolinium enhancement in
the myocardium and leads to insufficient contrast in LGE imaging as shown in Fig. 2. LGE: Late Gadolinium Enhancement
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reduce morbidity and mortality in a patient group at risk
for major adverse cardiac events. Currently two studies
are recruiting SSc patients eligible for autologous stem cell
transplantation, one in Chicago, IL, USA and one in
Tübingen, Germany (ClinicalTrials.gov NCT01445821;
NCT01895244) [34]. These studies aim to reduce cardiac
toxicity of the therapy regimen with effective use of stem
cell transplantation [11].
Study limitations
The study population is comparably small and the study
CMR image readers were biased by knowledge of histo-
pathologically proven involvement in SSc in all patients.
Only patients with severe disease were examined. Mild
and limited cutaneous SSc might present with less
pathologic CMR findings per individual. No T2 imaging
was performed, but non-quantitative T2 imaging cannot
reliably depict diffuse edema [35, 36] and edema has not
been found in previous reports [10]. Neither T1 nor T2-
mapping were available at the time patients were
examined.
Conclusions
CMR seems to be a valuable tool to identify and assess
the extent of cardiac involvement and therefore might
be useful for risk stratification and making a decision
upon therapeutic strategies. Myocardial involvement in
systemic sclerosis can be assumed if pathologic findings
in three categories are found: 1) pericardial effusion; 2)
ventricular kinesic pattern (LV and RV hypokinesia,
dyskinesia, dyssynchrony, and diastolic restriction); 3)
reduced LV-EF or RV-EF; 4) positive LGE or pathologic
inversion time localizer; 5) right ventricular dilatation.
Additional files
Additional file 1: SSFP loop of Fig. 1a in a female patient depicts
characteristically left ventricular and right ventricular restrictive filling
pattern in cardiac involvement in SSc. Systemic Sclerosis. (AVI 2 mb)
Additional file 2: The SSFP loop depicts minimal pericardial effusion and
right ventricular dilatation in a male patient in four-chamber view SSFP.
The loop demonstrates intraventricular and interventricular dyssynchrony
as well as restriction in diastole. SSFP: Steady State Free Precession. (AVI 1 mb)
Abbreviations
4CV: Four-chamber view; BSA: Body surface area; CI: Confidence interval;
CMR: Cardiovascular magnetic resonance; dcSSc: diffuse cutaneous SSc;
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enddiastolic volume; RV-EDVI: Right ventricular enddiastolic volume
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SD: Standard deviation; SSc: Systemic sclerosis; SSFP: Steady State Free
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